tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Spruce Biosciences granted breakthrough therapy designation to tralesinidase

Spruce Biosciences (SPRB) announced that the FDA has granted breakthrough therapy designation to tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1